Last reviewed · How we verify
DICL-SR
DICL-SR is a NSAID (nonsteroidal anti-inflammatory drug) Small molecule drug developed by Kunming Baker Norton Pharmaceutical Sales Co., Ltd.. It is currently FDA-approved for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.
DICL-SR is a sustained-release formulation of diclofenac that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide anti-inflammatory, analgesic, and antipyretic effects.
DICL-SR is a sustained-release formulation of diclofenac that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide anti-inflammatory, analgesic, and antipyretic effects. Used for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.
At a glance
| Generic name | DICL-SR |
|---|---|
| Sponsor | Kunming Baker Norton Pharmaceutical Sales Co., Ltd. |
| Drug class | NSAID (nonsteroidal anti-inflammatory drug) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2 enzymes, thereby decreasing prostaglandin production. The SR (sustained-release) formulation extends the drug's duration of action, allowing for less frequent dosing while maintaining therapeutic levels. This mechanism reduces inflammation, pain, and fever across various musculoskeletal and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Acute pain and inflammation
Common side effects
- Gastrointestinal upset (dyspepsia, abdominal pain)
- Nausea
- Headache
- Dizziness
- Increased risk of cardiovascular events (with long-term use)
- Increased risk of gastrointestinal bleeding
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DICL-SR CI brief — competitive landscape report
- DICL-SR updates RSS · CI watch RSS
- Kunming Baker Norton Pharmaceutical Sales Co., Ltd. portfolio CI
Frequently asked questions about DICL-SR
What is DICL-SR?
How does DICL-SR work?
What is DICL-SR used for?
Who makes DICL-SR?
What drug class is DICL-SR in?
What development phase is DICL-SR in?
What are the side effects of DICL-SR?
What does DICL-SR target?
Related
- Drug class: All NSAID (nonsteroidal anti-inflammatory drug) drugs
- Target: All drugs targeting COX-1 and COX-2
- Manufacturer: Kunming Baker Norton Pharmaceutical Sales Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Ankylosing spondylitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing